Hologic Inc. rallied in Wednesday’s extended session after the company said it plans to sell its stake in a blood screening business to Grifols for $1.85 billion in cash. The divestment is expected to improve the company’s “financial flexibility,” said Hologic in a statement. The deal is scheduled to close in the first quarter. Shares of Hologic were flat in late trade after closing at $40.79 in the regular session.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.